Post Marketing Information DHCPL 17/11/2022 Risk of major adverse cardiovascular events, malignancy, thrombosis and death associated with use of Janus Kinase (JAK) inhibitors
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Tablet, Film Coated, Extended Release 15 mg National Skin Centre
ORAL Select a brand starting with the letter: R RINVOQ EXTENDED-RELEASE TABLET 15MG [SIN15959P] RINVOQ EXTENDED-RELEASE TABLET 30MG [SIN16518P] RINVOQ EXTENDED-RELEASE TABLET 45MG [SIN16687P]